Roland E. Schmieder

Jun 24, 2024 | nature.com | Peter Rossing |David M. Charytan |José Luis Gorriz |Linong Ji |Roland E. Schmieder

AbstractPeople with type-2-diabetes (T2D) and chronic kidney disease (CKD), have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) independently reduce cardiovascular and kidney events. The effect of combining both is unclear.

May 30, 2023 | medscape.com | Roland E. Schmieder

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit.

Mar 27, 2023 | springermedizin.de | Roland E. Schmieder

Als chronische Nierenerkrankung (CKD, chronic kidney disease) wird definitionsgemäß eine seit mindestens 3 Monaten bestehende eingeschränkte Filtrationsleistung der Nieren aufgrund struktureller (UACR, Albumin-Kreatinin-Ratio) und funktioneller (eGFR, geschätzte glomeruläre Filtrationsrate) Veränderungen bezeichnet. Zu den häufigsten Ursachen für die progrediente Verschlechterung der Nierenfunktion bei Erwachsenen zählen Diabetes mellitus und arterielle Hypertonie.

Feb 28, 2023 | jamanetwork.com | Ajay Kirtane |Felix Mahfoud |Roland E. Schmieder |Friedrich Alexander

[Skip to Navigation] Figure 1.  Design of the 3 Studies Included in the Pooled AnalysisThe studies included in the pooled analysis are A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN SOLO and TRIO) and A Study of the ReCor Medical Paradise System in Stage II Hypertension (RADIANCE II) trials.